Literature DB >> 10946936

Augmentation of adipofascial flaps using the long-term local delivery of insulin and insulin-like growth factor-1.

E Yuksel1, A B Weinfeld, R Cleek, J Jensen, S Wamsley, J M Waugh, M Spira, S Shenaq.   

Abstract

The adipofascial flaps currently described in the literature frequently lack the volume requirements for reconstructive goals. In this study, the authors examined the use of long-term local delivery of insulin and insulin-like growth factor-1 (IGF-1) using polylactic-coglycolic acid/polyethylene glycol (PLGA/PEG) microspheres to augment inguinal adipofascial flaps based on the inferior epigastric vessels in the rat. Two flap models, the island flap and the limited dissection flap, were used to demonstrate simultaneous treatment and pretreatment modalities, respectively. Experimental groups received 12.5 mg of insulin microspheres (carrying 1 IU of insulin) plus 12.5 mg of IGF-1 microspheres (carrying 2.5 microg of IGF-1). A group undergoing the operation only (no treatment with microspheres) and a group treated with blank microspheres (no growth factor) served as external controls for the surgical procedure and the drug delivery device, respectively. In all groups (n = 5 animals in each), the contralateral flap served as an internal control. Upon harvest on postoperative day 28, the insulin and IGF-1-treated flaps in both models weighed statistically more than the internal control flaps and the two external control flaps. Likewise, on gross inspection, the adipogenic growth factor-treated flaps had greater volumes than the internal control flap groups and both of the external control flap groups (operation only and blank microspheres). Other intergroup comparisons suggested the absence of a systemic insulin and IGF-1 effect on adiposity. A histomorphometric analysis suggested (1) that insulin and IGF-1 treatment does not alter flap cell composition and (2) that flap augmentation is secondary to the stimulation of cell proliferation and adipocytic differentiation rather than the hypertrophy of mature adipocytes. Further evidence in favor of cell proliferation and differentiation was the discovery of nonanatomic, ectopic fat islands on the pedicle sheath of the treated flaps and the lack of variation in cell size distribution among groups. The authors concluded that the long-term local delivery of insulin and IGF-1 with PLGA/PEG microspheres is an effective method of adipofascial flap augmentation; this method increases the number of mature adipocytes rather than increasing the size of preexisting cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946936     DOI: 10.1097/00006534-200008000-00020

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  4 in total

1.  Injectable in situ forming biodegradable chitosan-hyaluronic acid based hydrogels for adipose tissue regeneration.

Authors:  Huaping Tan; J Peter Rubin; Kacey G Marra
Journal:  Organogenesis       Date:  2010 Jul-Sep       Impact factor: 2.500

2.  Engineering vascularized soft tissue flaps in an animal model using human adipose-derived stem cells and VEGF+PLGA/PEG microspheres on a collagen-chitosan scaffold with a flow-through vascular pedicle.

Authors:  Qixu Zhang; Justin Hubenak; Tejaswi Iyyanki; Erik Alred; Kristin C Turza; Greg Davis; Edward I Chang; Cynthia D Branch-Brooks; Elisabeth K Beahm; Charles E Butler
Journal:  Biomaterials       Date:  2015-09-18       Impact factor: 12.479

3.  Ischemia-reperfusion injury of adipofascial tissue: an experimental study evaluating early histologic and biochemical alterations in rats.

Authors:  Yusuf Kenan Coban; Ergul Belge Kurutas; Harun Ciralik
Journal:  Mediators Inflamm       Date:  2005-10-24       Impact factor: 4.711

4.  Silicon-Enhanced Adipogenesis and Angiogenesis for Vascularized Adipose Tissue Engineering.

Authors:  Xiaoya Wang; Long Gao; Yan Han; Min Xing; Cancan Zhao; Jinliang Peng; Jiang Chang
Journal:  Adv Sci (Weinh)       Date:  2018-09-30       Impact factor: 16.806

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.